Amyris Launches Pathways Program
January 15 2016 - 8:30AM
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company,
today announced the availability of its Pathways Program, a program
that provides partners a low-cost, low-risk opportunity to access
Amyris’s industry-leading synthetic biology technology. Through the
Pathways Program, partners can, with a small initial investment,
sponsor and secure a molecule they are interested in having Amyris
produce using the next-generation tools and technologies being
developed through the company’s recently announced technology
investment agreement with the Defense Advanced Research Projects
Agency (DARPA). Amyris expects the powerful combination of its
existing core technology and bioengineering advancements enabled by
its project with DARPA will significantly reduce the time and cost
of bringing new molecules to market using industrial biotechnology.
The Pathways Program allows partners to access these latest
developments and explore bio-synthetic production opportunities
with minimal risk and commitment.
Provides Partners a De-Risked Opportunity to Explore Development
of New Molecules with a Leader in Synthetic Biology
The Pathways Program provides partners with a de-risked
opportunity to use Amyris’s expert capabilities and advanced tools
and methodologies for the construction of organisms that convert
sugar to the partner’s target molecule. The successful completion
of the organism engineering potentially provides a new mode of
production with secure stable supply from a renewable resource.
In essence, this program opens up Amyris’s advanced technology
platform and leading capabilities to researchers and companies
wishing to determine the viability of biological production of
target molecules at a lower cost and with minimized risk.
“Our Pathways Program provides partners with a unique and
advantaged opportunity to access cutting-edge technologies that are
at the forefront of bioengineering to explore the development of
new materials with little upfront risk,” said John Melo, President
& CEO at Amryis. “Our mission is to accelerate the transition
to a world that uses sustainably sourced bio-materials and we
believe that making our technology more accessible removes a key
barrier to making lower cost, higher performing products for a
healthier planet. We have now created several $100-million-dollar
supply opportunities for our renewable farnesene technology and
expect many more building blocks, like farnesene, to come from
opening our platform to the world.”
For partners interested in accessing faster, lower cost to
market for sustainable biochemistry please contact Cindy Bryant,
Amyris’s Senior Vice President Corporate Development &
Collaborations at 510-450-0761 ext. 468.
About Amyris
Amyris is the integrated renewable products company that is
enabling the world’s leading brands to achieve sustainable growth.
Amyris applies its innovative bioscience solutions to convert plant
sugars into hydrocarbon molecules, specialty ingredients and
consumer products. The company is delivering its No Compromise®
products in focused markets, including specialty and performance
chemicals, fragrance ingredients, and cosmetic emollients. More
information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any
statements other than statements of historical facts could be
deemed to be forward-looking statements. These forward-looking
statements include, among other things, statements regarding future
events (such as Amyris’s ability to offer molecule development
services at low risk and low cost to potential partners and the
ability of Amyris technology, existing and under development, to
significantly reduce the time and cost of bringing new molecules to
market using industrial biotechnology), that involve risks and
uncertainties. These statements are based on management's current
expectations and actual results and future events may differ
materially due to risks and uncertainties, including those
associated with any delays or failures in development, production
and commercialization of products, liquidity and ability to fund
capital expenditures, Amyris's reliance on third parties to achieve
its goals, and other risks detailed in the "Risk Factors" section
of Amyris's quarterly report on Form 10-Q filed on November 9,
2015. Amyris disclaims any obligation to update information
contained in these forward-looking statements whether as a result
of new information, future events, or otherwise.
Amyris and the Amyris logo are registered trademarks of Amyris,
Inc. All other trademarks are the property of their respective
owners.
Contacts:Peter DeNardoDirector, Investor
Relations and Corporate CommunicationsAmyris, Inc. +1 (510)
740-7481investor@amyris.compr@amyris.com
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From Apr 2023 to Apr 2024